Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zymeworks Inc 108 PATRIOT DRIVE SUITE A MIDDLETOWN DE 19709 USA

www.zymeworks.com Employees: 286 P: 302-274-8744

Sector:

Medical

Description:

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 1,962,226
Enterprise Value, $K 1,896,126
Shares Outstanding, K 74,837
Annual Sales, $ 76,300 K
Annual Net Income, $ -122,700 K
Last Quarter Sales, $ 27,610 K
Last Quarter Net Income, $ -19,600 K
EBIT, $ -70,610 K
EBITDA, $ -59,420 K
60-Month Beta 1.27
% of Insider Shareholders 33.51%
% of Institutional Shareholders 92.89%
Float, K 49,759
% Float 66.49%
Short Volume Ratio 0.36

Growth:

1-Year Return 87.95%
3-Year Return 295.23%
5-Year Return -48.59%
5-Year Revenue Growth 158.29%
5-Year Earnings Growth 63.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.26 on 11/06/25
Next Earnings Date N/A
Earnings Per Share ttm -0.84
EPS Growth vs. Prev Qtr -966.67%
EPS Growth vs. Prev Year 33.33%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ZYME Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -19.25%
Return-on-Assets % -14.97%
Profit Margin % -160.81%
Debt/Equity 0.00
Price/Sales 24.62
Price/Cash Flow N/A
Price/Book 5.89
Book Value/Share 4.26
Interest Coverage -0.48
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar